How should bromocriptine be used to treat persistent central fever, including recommended dosing, contraindications, and monitoring?

Bromocriptine for Central Fever

Bromocriptine should be initiated at 2.5 mg twice daily (or 5 mg every 8 hours) with food for persistent central fever after excluding infectious causes, with dose titration every 2-7 days up to 7.5-15 mg daily based on temperature response.

Diagnostic Prerequisites

Before initiating bromocriptine, you must establish central (neurogenic) fever by:

• Core temperature >37.5°C (some define as >38.3°C) persisting despite standard antipyretics 1
• Exclusion of infectious sources: negative cultures, normal inflammatory markers (CRP, procalcitonin), no infiltrates on imaging 2, 3
• Presence of acute neurologic injury: traumatic brain injury, intracerebral hemorrhage, subarachnoid hemorrhage, or spinal cord injury 1, 4, 5
• Failure of conventional antipyretics and cooling measures 6, 4

Central fever results from disruption of hypothalamic thermoregulatory pathways and should be distinguished from infectious fever, though both warrant temperature control in brain-injured patients to prevent secondary injury 1.

Dosing Protocol

Initial Dosing

Start with 2.5 mg orally twice daily with food 7. Alternative regimens include:

• 5 mg every 8 hours (most commonly used in neurocritical care) 6, 4
• 2.5 mg daily if concerned about tolerability 7

Dose Escalation

• Increase by 2.5 mg every 2-7 days based on temperature response 7
• Target dose range: 7.5-15 mg daily (divided doses) 6, 4
• Maximum studied dose: 40 mg daily, though most patients respond to lower doses 8
• Maximal FDA-approved dose: 100 mg/day (though rarely needed for fever) 7

Expected Response Timeline

• Temperature reduction begins within 24 hours 8, 5
• Peak effect at 48-72 hours: expect 0.5-0.7°C reduction 8
• Complete defervescence typically within 24-72 hours 4, 5

Monitoring Requirements

Temperature Monitoring

• Use central temperature methods (bladder catheter, esophageal probe, pulmonary artery catheter) when available over peripheral methods 3
• Monitor temperature every 4 hours initially, then every 6-8 hours once stable

Safety Monitoring

• Liver function tests at baseline and weekly (hepatotoxicity is the most common adverse effect) 4
• Blood pressure and heart rate (risk of hypotension, though rare)
• Mental status (sedation possible but uncommon)
• Assess for nausea, which can be mitigated by taking with food 7

Duration of Therapy

• Continue until fever resolves and patient stabilizes neurologically 4
• Typical duration: 5-160 days (median 13 days in clinical practice) 8
• Taper gradually when discontinuing after prolonged use (>2 weeks)

Contraindications

Absolute Contraindications

• Uncontrolled hypertension 7
• Hypersensitivity to ergot alkaloids 7
• Peripartum cardiomyopathy or recent myocardial infarction (historical association with thromboembolic events) 9

Relative Contraindications

• Severe hepatic impairment (monitor closely)
• Concurrent use of strong CYP3A4 inhibitors
• Psychotic disorders (dopamine agonism may worsen)

Important Caveat for Peripartum Patients

If treating a postpartum woman with suspected central fever, ensure adequate anticoagulation if LVEF is reduced, as bromocriptine has historical associations with thromboembolism in this population 9. However, this is primarily relevant for lactation suppression doses, not fever management.

Adjunctive Measures

Continue concurrent therapies while initiating bromocriptine:

• Acetaminophen (bromocriptine plus acetaminophen is more effective than acetaminophen alone) 6
• Surface cooling devices as needed 8
• Treat underlying brain injury and elevated ICP per standard protocols 1

Do not delay bromocriptine initiation waiting for complete resolution of fever with other measures if central fever is suspected—the combination approach is superior 6.

Clinical Pearls

• Bromocriptine works through dopaminergic modulation of hypothalamic thermoregulation, not through peripheral antipyretic mechanisms 8, 5
• The modest temperature reduction (0.5-0.7°C) is clinically meaningful in preventing secondary brain injury 8
• Adverse effects are rare and mild: hepatotoxicity (most common), nausea, sedation 4
• No significant drug interactions with standard neurocritical care medications
• This is an off-label use—FDA approval is for hyperprolactinemia, acromegaly, and Parkinson's disease 7

When to Discontinue

Stop bromocriptine if:

• Fever resolves and remains controlled for 48-72 hours 4
• Hepatotoxicity develops (elevated transaminases >3x upper limit of normal)
• Patient develops intolerable side effects
• Alternative diagnosis for fever is identified requiring different treatment

The evidence base consists primarily of retrospective cohort studies and case reports 6, 4, 8, 5, 10, with one small randomized trial showing non-significant trends 11. However, the consistent signal across multiple studies, favorable safety profile, and lack of effective alternatives support its use in refractory central fever.